Columbia University - Boston Biomedical Collaboration

CU BBI

Columbia University is pleased to announce the annual Boston Biomedical - Columbia Research Collaboration Call for Short Proposals. The collaboration stimulates research and development in the field of oncology through collaborative, Columbia investigator initiated projects.

This Request for Proposals (RFP) is seeking innovative projects toward the discovery and development of novel oncology therapeutics and platform technologies.

Read the full request for proposals below or download here

Questions? Please read FAQs here.

Request for Short Proposals
Timeline
Application Process

Applicants should develop a 2-4 page, Non-Confidential Short Proposal using the 2019 Boston Biomedical – Columbia RFP proposal submission template. Applicants can submit more than one proposal. We recommend that you reach out to Columbia Technology Ventures at techventures@columbia.edu to discuss your idea before submitting a proposal.

Submit a Non-Confidential Short Proposal Here 

Review Process and Selection of Final Award Recipients

Boston Biomedical will review the non-confidential Short Proposals and determine further interest in the development of a confidential Full Proposal. Full Proposals will be written by the applicants in collaboration with Boston Biomedical’s scientists. This stage will involve meetings between the selected proposal finalists and Boston Biomedical’s scientists. Boston Biomedical will select the final award recipients after submission of the Full Proposals. Award recipients are encouraged to submit their funded research outcomes for publication in academic journals, as they would for other university research.

About Boston Biomedical

Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. As a fully integrated oncology drug research and development company, Boston Biomedical, Inc. has established a track record of accomplishments, including advancing the research and development of multiple compounds and clinical programs. The company’s range of expertise includes drug discovery, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs and commercialization. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan.